ReachRxResearch
Home
Research
Sign Up
Personalised dupilumab therapy in severe asthma: real-world dosing interval prolongation among early responders
Back to Research Hub
  1. Home
  2. Research Hub
  3. Personalised dupilumab therapy in severe…

Personalised dupilumab therapy in severe asthma: real-world dosing interval prolongation among early responders

The Journal of Allergy and Clinical Immunology: In Practice·October 23Open Access
AllergyPractice changingSevere Uncontrolled AsthmaProspective Cohort StudyBiologicIL-4/IL-13 Receptor AntagonistAdultDupixentDupilumab

Summary

View source

What was studied

In 24 adults with severe uncontrolled asthma who were early responders to dupilumab, this study assessed whether extending the dosing interval beyond the licensed every-2-weeks schedule could maintain disease control, comparing outcomes at baseline (pre-biologic), after standard 2-week dosing (~6.7 months), and after interval prolongation (~8.6 months further).

Key findings

Extending the median dosing interval to every 4 weeks (range 2–6 weeks) maintained disease control: FEV1% predicted stayed stable (93.5% → 94.2%), FeNO remained suppressed (22.8 → 24.9 ppb), ACQ-6 stayed low (0.7 → 0.5), and annualized exacerbation rate remained 0.0 — all with no statistically significant difference between the standard-dosing and prolonged-dosing visits.

Study limitations

Very small sample size (n=24) with no control group, limiting generalizability; patients were selected as 'early responders,' so findings may not apply to all dupilumab users; no randomization or blinding.

Clinical implications

In carefully selected dupilumab early responders with severe asthma, extending the dosing interval to every 4 weeks appears feasible without losing disease control, which could reduce drug costs and injection burden — but larger controlled studies are needed before adopting this routinely.

Caveats

  • All patients were OCS-free at baseline, limiting applicability to patients on maintenance oral corticosteroids
  • No randomized control group; disease stability over time cannot be fully attributed to the interval prolongation strategy
  • Participants were pre-selected as 'early responders,' introducing selection bias — patients who did not respond well to dupilumab were excluded
Show all 4
  • Sample size is very small (n=24); results should be interpreted with caution

Related Questions

Explore related topics

dupilumab dose interval extension severe asthma real-world outcomesbiologic dose tapering or prolongation in type 2 airway diseasedupilumab personalized dosing cost-effectiveness asthma

Publication Details

Year
2026
Journal
The Journal of Allergy and Clinical Immunology: In Practice
Sample Size
n=24
Source
View article
Keep scrolling
More content below.
Up Next